{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T08:36:26Z","timestamp":1724834186201},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,20]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To investigate the usefulness of severity classification for predicting outcomes in patients with adult-onset Still\u2019s disease (AOSD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a multi-centre retrospective cohort study. AOSD patients were classified into mild, moderate, and severe groups based on severity classification (Japanese Ministry of Health, Labour and Welfare) during the initial treatment, and clinical features were compared among these groups. The primary endpoints were the AOSD-related mortality and drug-free remission rate. For comparison, the same analysis was performed in parallel for patient groups stratified by the modified Pouchot systemic score.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>According to severity classification, 49 (35%), 37 (26%), and 56 patients (39%) were classified into mild, moderate, and severe groups, respectively. Patients in the severe group showed higher frequency of severe complications and the use of biological agents. Although AOSD-related survival was not significantly different (p\u2009=\u2009.0776), four of the five fatal cases were classified into the severe group. The severe group showed a reduced rate of drug-free remission (p\u2009=\u2009.0125). Patient groups classified by systemic score did not correlate with survival or drug-free remission.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Severity classification is useful for predicting outcomes in patients with AOSD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roab083","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T19:55:35Z","timestamp":1634759735000},"page":"953-959","source":"Crossref","is-referenced-by-count":1,"title":["Usefulness of the severity classification for predicting drug-free remission in Japanese patients with adult-onset Still\u2019s disease"],"prefix":"10.1093","volume":"32","author":[{"given":"Akihito","family":"Maruyama","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Faculty of Medicine, Saga University , Saga, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Kokuzawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Jichi Medical University , Shimotsuke, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences , Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Kirino","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideto","family":"Nagai","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Inoue","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Japanese Red Cross Fukuoka Hospital , Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Ota","sequence":"additional","affiliation":[{"name":"Center for Rheumatic Diseases, Iizuka Hospital , Iizuka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Chifu","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Saiseikai Karatsu Hospital , Karatsu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satomi","family":"Inokuchi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences , Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Mitoma","sequence":"additional","affiliation":[{"name":"Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences , Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuteru","family":"Akahoshi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Faculty of Medicine, Saga University , Saga, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Faculty of Medicine, Saga University , Saga, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihide","family":"Ohta","sequence":"additional","affiliation":[{"name":"Suigo-en Kohokai Group Medical Corporation , Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Jichi Medical University , Shimotsuke, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifumi","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Faculty of Medicine, Saga University , Saga, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,10,1]]},"reference":[{"key":"2022082013391596100_R1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/ard.30.2.121","article-title":"Still\u2019s disease in the adult","volume":"30","author":"Bywaters","year":"1971","journal-title":"Ann Rheum Dis"},{"key":"2022082013391596100_R2","first-page":"1139","article-title":"Adult Still\u2019s disease: review of 228 cases from the literature","volume":"14","author":"Ohta","year":"1987","journal-title":"J Rheumatol"},{"key":"2022082013391596100_R3","first-page":"1058","article-title":"Adult Still\u2019s disease: a multicenter survey of Japanese patients","volume":"17","author":"Ohta","year":"1990","journal-title":"J Rheumatol"},{"key":"2022082013391596100_R4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3109\/14397595.2014.974881","article-title":"Nationwide epidemiological survey of 169 patients with adult Still\u2019s disease in Japan","volume":"25","author":"Asanuma","year":"2015","journal-title":"Mod Rheumatol"},{"key":"2022082013391596100_R5","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s10067-016-3308-8","article-title":"Adult-onset Still\u2019s disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients","volume":"35","author":"Sfriso","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2022082013391596100_R6","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1136\/ard.2005.046904","article-title":"Reactive haemophagocytic syndrome in adult-onset Still\u2019s disease: a report of six patients and a review of the literature","volume":"65","author":"Arlet","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2022082013391596100_R7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10067-014-2487-4","article-title":"Life-threatening complications of adult- onset Still\u2019s disease","volume":"33","author":"Efthimiou","year":"2014","journal-title":"Clin Rheumatol"},{"key":"2022082013391596100_R8","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/art.38672","article-title":"Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adults","volume":"66","author":"Kumakura","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2022082013391596100_R9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jaut.2018.07.018","article-title":"A comprehensive review on adult onset Still\u2019s disease","volume":"93","author":"Giacomelli","year":"2018","journal-title":"J Autoimm"},{"key":"2022082013391596100_R10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s12026-014-8561-9","article-title":"Pathogenesis of adult-onset Still\u2019s disease: new insights from the juvenile counterpart","volume":"61","author":"Jamilloux","year":"2015","journal-title":"Immunol Res"},{"key":"2022082013391596100_R11","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","article-title":"Mechanisms, biomarkers and targets for adult-onset Still\u2019s disease","volume":"14","author":"Feist","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2022082013391596100_R12","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1838-6","article-title":"Adult-onset Still\u2019s disease biological treatment strategy may depend on the phenotypic dichotomy","volume":"21","author":"Vercruysse","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2022082013391596100_R13","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1080\/14712598.2019.1652591","article-title":"Biologica for the treatment of adult-onset still\u2019s disease","volume":"19","author":"Yoo","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"2022082013391596100_R14","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/00005792-199103000-00004","article-title":"Adult Still\u2019s disease: manifestations, disease course, and outcome in 62 patients","volume":"70","author":"Pouchot","year":"1991","journal-title":"Medicine"},{"key":"2022082013391596100_R15","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.3899\/jrheum.100247","article-title":"Clinical manifestations but not cytokine profiles differentiate adult-onset Still\u2019s disease and sepsis","volume":"37","author":"Rau","year":"2010","journal-title":"J Rheumatol"},{"key":"2022082013391596100_R16","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-016-0738-8","article-title":"Adult-onset Still\u2019s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers","volume":"14","author":"Ruscitti","year":"2016","journal-title":"BMC Med"},{"key":"2022082013391596100_R17","first-page":"S83","article-title":"Predictive factors and prognosis of macrophage activation syndrome associated with adult-onset Still\u2019s disease","volume":"37","author":"Yang","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2022082013391596100_R18","first-page":"28","article-title":"Clinical features and prognosis in 82 patients with adult-onset Still\u2019s disease","volume":"32","author":"Kim","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2022082013391596100_R19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235326","article-title":"Ferritin and C-reactive protein are predictive biomarker of mortality and macrophage activation syndrome in adult onset Still\u2019s disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Rheumatologia Clinica e Sperimentale (GIRRCS) cohort","volume":"15","author":"Benedetto","year":"2020","journal-title":"PLoS One"},{"key":"2022082013391596100_R20","first-page":"S23","article-title":"Adult-onset Still\u2019s disease-associated interstitial lung disease represents severe phenotype of the disease with higher rate of haemophagocytic syndrome and relapse","volume":"37","author":"Takakuwa","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2022082013391596100_R21","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1093\/rheumatology\/keab023","article-title":"Characteristics and risk factors of relapses in patients with adult-onset Still\u2019s disease: a long-term cohort study","volume":"60","author":"Meng","year":"2021","journal-title":"Rheumatology"},{"key":"2022082013391596100_R22","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1080\/14397595.2020.1829340","article-title":"Clinical features of elderly-onset adult-onset Still\u2019s disease","volume":"31","author":"Maruyama","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2022082013391596100_R23","volume-title":"Clinical Practice Guideline for Adult Still\u2019s Disease 2017 (Clinical Practice Guideline Committee for Adult Still\u2019s Disease Organized by the Research Team for Autoimmune Diseases, the Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare, in Japanese)","author":"Sumida","year":"2017"},{"key":"2022082013391596100_R24","first-page":"424","article-title":"Preliminary criteria for classification of adult Still\u2019s disease","volume":"19","author":"Yamaguchi","year":"1992","journal-title":"J Rheumatol"},{"key":"2022082013391596100_R25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/s10165-004-0293-6","article-title":"Autoimmune-associated hemophagocytic syndrome","volume":"14","author":"Kumakura","year":"2004","journal-title":"Mod Rheumatol"},{"key":"2022082013391596100_R26","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH 2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"2022082013391596100_R27","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00296-018-4114-1","article-title":"Are the 2016 EULAR\/ACR\/PRINTO classification criteria for macrophage activation syndrome applicable to patients with adult-onset Still\u2019s disease?","volume":"39","author":"Tada","year":"2019","journal-title":"Rheumatol Int"},{"key":"2022082013391596100_R28","doi-asserted-by":"crossref","DOI":"10.1186\/s12959-016-0117-x","article-title":"DIC subcommittee of the Japanese Society on Thrombosis and Hemostasis: proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis","volume":"14","author":"Asakura","year":"2016","journal-title":"Thromb J"},{"key":"2022082013391596100_R29","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/annrheumdis-2015-208982","article-title":"2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. A European League Against Rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation collaborative initiative","volume":"75","author":"Ravelli","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022082013391596100_R30","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3899\/jrheum.161286","article-title":"Application of the 2016 EULAR\/ACR\/PRINTO classification criteria for macrophage activation syndrome in patients with adult-onset Still disease","volume":"44","author":"Ahn","year":"2017","journal-title":"J Rheumatol"},{"key":"2022082013391596100_R31","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015123","article-title":"Managing adult-onset Still\u2019s disease: the effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study","volume":"98","author":"Ruscitti","year":"2019","journal-title":"Medicine"},{"key":"2022082013391596100_R32","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000023579","article-title":"Risk factors associated with relapse of adult-onset Still disease in Korean patients","volume":"99","author":"Kang","year":"2020","journal-title":"Medicine"},{"key":"2022082013391596100_R33","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-2021-9","article-title":"Management of adult-onset Still\u2019s disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts","volume":"21","author":"Colafrancesco","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2022082013391596100_R34","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3109\/s10165-011-0569-6","article-title":"Therapeutic response of patients with adult Still\u2019s disease to biologic agents: multicenter results in Japan","volume":"22","author":"Suematsu","year":"2012","journal-title":"Mod Rheumatol"},{"key":"2022082013391596100_R35","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","article-title":"Tocilizumab in patients with adult-onset still\u2019s disease refractory to glucocorticoid treatment: a randomized, double-blind, placebo-controlled phase III trial","volume":"77","author":"Kaneko","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2022082013391596100_R36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00296-019-04358-w","article-title":"Prescribing motivations and patients\u2019 characteristics related to the use of biologic drugs in adult-onset Still\u2019s disease: analysis of a multicentre \u2018real-life\u2019 cohort","volume":"40","author":"Ruscitti","year":"2020","journal-title":"Rheumatol Int"},{"key":"2022082013391596100_R37","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1177\/0961203320901594","article-title":"Adult macrophage activation syndrome-haemophagocytic lymphohistiocytosis: \u2018of plasma exchange and immunosuppressive escalation strategies\u2019 - a single centre reflection","volume":"29","author":"Lorenz","year":"2020","journal-title":"Lupus"},{"key":"2022082013391596100_R38","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-235786","article-title":"Adult-onset Still\u2019s disease with concurrent thrombotic thrombocytopenic purpura: case report and literature review","volume":"13","author":"Kato","year":"2020","journal-title":"BMJ Case Rep"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roab083\/41928295\/roab083.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/5\/953\/45487203\/roab083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/5\/953\/45487203\/roab083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T13:40:10Z","timestamp":1661002810000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/32\/5\/953\/6378736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,10,1]]},"published-print":{"date-parts":[[2022,8,20]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roab083","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2021,10,1]]}}}